Retatrutide

Synonyms: Retatrutide, 2381089-83-2, GIP/GLP-1/Glucagon receptor triagonist, (E)-retatrutide

Retatrutide is a synthetic peptide analog that functions as a triple agonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Developed for the management of obesity and type 2 diabetes, it represents a next-generation incretin-based therapy that combines the metabolic benefits of three key hormones in a single molecule.

The peptide is composed of a 39-amino acid sequence with an N-terminal fatty acid modification that enhances its pharmacokinetic profile, extending its half-life and enabling once-weekly dosing. Its unique mechanism of action coordinates insulin secretion, glucagon suppression, and energy expenditure, resulting in pronounced weight loss and glycemic control in clinical studies.

Retatrutide is supplied as a lyophilized powder for research and development purposes. It is intended for laboratory use only and is not approved for human or veterinary therapeutic use.

Function

• Triple agonism: Activates GIP, GLP-1, and glucagon receptors.
• Weight management: Reduces appetite and increases energy expenditure.
• Glycemic control: Enhances insulin secretion and improves insulin sensitivity.
• Research tool: Used in studies of metabolic disorders and incretin biology.

Source & Standardization

• Source: Synthetic peptide, produced by solid-phase peptide synthesis.
• Standardization: Purity ≥98% (HPLC).
• Forms: Lyophilized powder.
• Applications: Research and development in metabolic disease.

Specifications

Documentation & Supply

• MOQ: 5g
• Lead time: 5-7 business days after order confirmation.
• Documentation: COA, MSDS, TDS available.
• Packaging: Sealed vials, custom packaging on request.

Request For Quote

• Our Address: 280 Main Street, Xian, Shaanxi, China
• LyvBio Co., Ltd. — Email: info@lyvbio.com